Equity Overview
Price & Market Data
Price: $5.61
Daily Change: -$0.045 / 0.80%
Daily Range: $5.41 - $5.76
Market Cap: $17,647,760
Daily Volume: 21,098
Performance Metrics
1 Week: -12.60%
1 Month: -36.39%
3 Months: -18.09%
6 Months: -53.17%
1 Year: -67.00%
YTD: -50.53%
Company Details
Employees: 60
Sector: Health technology
Industry: Biotechnology
Country:
Details
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is based in Philadelphia, Pennsylvania.